Genfit
Aperta
SettoreSettore sanitario
13.32 3.42
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
12.76
Massimo
13.44
Entrata | -76M |
|---|---|
Vendite | 32M |
EPS | -1.525 |
Margine di Profitto | -237.939 |
Dipendenti | 188 |
EBITDA | -7M |
Utili prossimi | 29 set 2026 |
|---|
Capitalizzazione di Mercato | 674M |
|---|---|
Apertura precedente | 9.9 |
Chiusura precedente | 13.32 |
Notizie sul Sentiment di mercato
By Acuity
65%
35%
302 / 342 Classifica in Healthcare
Genfit Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Notizie correlate
Confronto tra pari
Modifica del prezzo
Genfit Previsione
Sentiment
By Acuity
302 / 342 Classifica in Settore sanitario
Notizie sul Sentiment di mercato
Prove ribassiste
Volatilità
Sotto la media
Volume delle notizie (RCV)
Sopra la media
Notizie finanziarie
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$
Chi Siamo Genfit
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.